A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection.

Zhong-Zheng Zhu,Wen-Ming Cong,Shu-Fang Liu,Zhi-Hong Xian,Wei-Qing Wu,Meng-Chao Wu,Bin Gao,Li-Fang Hou,Guan-Shan Zhu
DOI: https://doi.org/10.1016/j.canlet.2005.04.014
IF: 9.756
2005-01-01
Cancer Letters
Abstract:To clarify the modifying effect of the codon 72 p53 polymorphism on hepatocellular carcinoma (HCC) stratified by chronic hepatitis B virus (HBV) infection status, 111 incident cases of HCC and 424 controls in HBV-negative subjects and 135 cases and 125 controls in HBV-positive subjects were identified. No correlation between the polymorphism and HCC risk was found when comparing the HBV-positive cases to controls. However, in HBV-negative subjects, Arg/Pro and Pro/Pro genotypes had a 1.97-fold and a 3.36-fold increased risk for HCC, respectively. In subjects with the Pro allele and family history of HCC yielded an 11.81-fold increased risk of HCC.
What problem does this paper attempt to address?